These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20371445)

  • 1. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma.
    Avilés A; Neri N; Huerta-Guzmán J; de Jesús Nambo M
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):125-8. PubMed ID: 20371445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
    Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
    J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
    Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
    Pytlík R; Belada D; Kubáčková K; Vášová I; Kozák T; Pirnos J; Bolomská I; Matuška M; Přibylová J; Campr V; Burešová L; Sýkorová A; Berková A; Klener P; Trněný M;
    Leuk Lymphoma; 2015 Jan; 56(1):57-64. PubMed ID: 24628294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
    J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
    Imataki O; Tamai Y; Kawakami K
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1629-32. PubMed ID: 17940378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Boonlerd P; Tantiworawit A; Norasetthada L; Chai-Adisaksopha C; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Rattarittamrong E
    Ann Med; 2023; 55(2):2261109. PubMed ID: 37748107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy.
    Suzuki T; Koga H; Yamazaki S; Saeki H; Tanaka H; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
    Clin Ther; 2008 Jun; 30(6):1155-9. PubMed ID: 18640471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
    Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
    Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
    Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
    J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Montoro J; Andreola G; Gardellini A; Babic A; Negri M; Frungillo N; Martinelli G; Laszlo D
    Transfus Apher Sci; 2014 Jun; 50(3):411-4. PubMed ID: 24751603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.
    Kim DY; Nam J; Chung JS; Kim SW; Shin HJ
    Cancer Res Treat; 2022 Jan; 54(1):301-313. PubMed ID: 33940789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
    Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
    Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.